Literature DB >> 25445164

Different clinicopathological features between patients who developed early and late recurrence following surgery for renal cell carcinoma.

Yoichi Fujii1, Masaomi Ikeda, Kazuhiro Kurosawa, Mariko Tabata, Takayuki Kamigaito, Chihiro Hosoda, Toshikazu Okaneya.   

Abstract

BACKGROUND: To evaluate the clinicopathological features and identify predictive factors in patients with early and late recurrence following initial surgery for localized renal cell carcinoma.
METHODS: From April 1988 to January 2013, 486 patients without metastases at the initial diagnosis underwent either radical nephrectomy or partial nephrectomy and were followed up thereafter. Patients were divided into 3 groups; no recurrence, early recurrence (recurrence within 5 years), and late recurrence (recurrence after 5 years). Cancer-specific survival after recurrence was analyzed by using the Kaplan-Meier method. Multivariate logistic regression analysis was applied to define clinical and pathological factors correlated to early and late recurrence following surgery.
RESULTS: Seventy-seven (15.8 %) and 18 (3.7 %) patients developed early and late recurrence, respectively. In multivariate logistic regression analysis, positive symptoms at diagnosis, ≥pT2, positive lymphovascular invasion, and grade 3 were independent predictive factors for early recurrence. Age at surgery and ≥pT2 were significantly correlated to late recurrence. The 5-year cancer-specific survival rate after recurrence was 72.4 and 52.9 % in the late and the early recurrence groups, respectively (P = 0.044).
CONCLUSIONS: The risk factors for clinical recurrence differed according to the time that had elapsed between initial surgery and the first metastasis in patients with localized renal cell carcinoma. Our study showed age at initial surgery and the pT stage were independent predictive factors for late recurrence. Further investigation of a larger number of patients is required to predict which patients may develop recurrence in the future and to choose appropriate treatment.

Entities:  

Mesh:

Year:  2014        PMID: 25445164     DOI: 10.1007/s10147-014-0775-2

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  28 in total

1.  Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer.

Authors:  S Braun; K Pantel; P Müller; W Janni; F Hepp; C R Kentenich; S Gastroph; A Wischnik; T Dimpfl; G Kindermann; G Riethmüller; G Schlimok
Journal:  N Engl J Med       Date:  2000-02-24       Impact factor: 91.245

2.  Sorafenib in advanced clear-cell renal-cell carcinoma.

Authors:  Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

3.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

4.  Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis.

Authors:  John M Hollingsworth; David C Miller; Stephanie Daignault; Brent K Hollenbeck
Journal:  Cancer       Date:  2007-05-01       Impact factor: 6.860

5.  Recurrence of renal cell carcinoma more than 5 years after nephrectomy.

Authors:  Kohsuke Uchida; Noriomi Miyao; Naoya Masumori; Atsushi Takahashi; Toshiro Oda; Masahiro Yanase; Hiroshi Kitamura; Naoki Itoh; Masaaki Sato; Taiji Tsukamoto
Journal:  Int J Urol       Date:  2002-01       Impact factor: 3.369

Review 6.  Prognostic factors in renal cancer.

Authors:  J B Thrasher; D F Paulson
Journal:  Urol Clin North Am       Date:  1993-05       Impact factor: 2.241

7.  Systemic spread is an early step in breast cancer.

Authors:  Yves Hüsemann; Jochen B Geigl; Falk Schubert; Piero Musiani; Manfred Meyer; Elke Burghart; Guido Forni; Roland Eils; Tanja Fehm; Gert Riethmüller; Christoph A Klein
Journal:  Cancer Cell       Date:  2008-01       Impact factor: 31.743

8.  Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project).

Authors:  Sabine Brookman-May; Matthias May; Shahrokh F Shariat; Evanguelos Xylinas; Christian Stief; Richard Zigeuner; Thomas Chromecki; Maximilian Burger; Wolf F Wieland; Luca Cindolo; Luigi Schips; Ottavio De Cobelli; Bernardo Rocco; Cosimo De Nunzio; Bogdan Feciche; Michael Truss; Christian Gilfrich; Sascha Pahernik; Markus Hohenfellner; Stefan Zastrow; Manfred P Wirth; Giacomo Novara; Marco Carini; Andrea Minervini; Claudio Simeone; Alessandro Antonelli; Vincenzo Mirone; Nicola Longo; Alchiede Simonato; Giorgio Carmignani; Vincenzo Ficarra
Journal:  Eur Urol       Date:  2012-06-22       Impact factor: 20.096

9.  Prognostic factors in metastatic renal carcinoma.

Authors:  J D Maldazys; J B deKernion
Journal:  J Urol       Date:  1986-08       Impact factor: 7.450

10.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

Authors:  Gary Hudes; Michael Carducci; Piotr Tomczak; Janice Dutcher; Robert Figlin; Anil Kapoor; Elzbieta Staroslawska; Jeffrey Sosman; David McDermott; István Bodrogi; Zoran Kovacevic; Vladimir Lesovoy; Ingo G H Schmidt-Wolf; Olga Barbarash; Erhan Gokmen; Timothy O'Toole; Stephanie Lustgarten; Laurence Moore; Robert J Motzer
Journal:  N Engl J Med       Date:  2007-05-31       Impact factor: 91.245

View more
  6 in total

Review 1.  Secondary metastatic lesions to colon and rectum.

Authors:  Michail Galanopoulos; Filippos Gkeros; Christos Liatsos; Christos Pontas; Apostolis Papaefthymiou; Nikos Viazis; Gerassimos J Mantzaris; Nikolaos Tsoukalas
Journal:  Ann Gastroenterol       Date:  2018-03-03

2.  Asynchronous abdominal wall and sigmoid metastases in clear cell renal cell carcinoma: A case report and literature review.

Authors:  Fangyuan Zhang; Gang Zhao; Pengjie Wu; Qi An; Yang Yang; Xin Chen; Jianye Wang; Dong Wei
Journal:  Asian J Urol       Date:  2018-01-06

3.  Colonic metastasis of renal cell carcinoma following curative nephrectomy: A case report and review of the literature.

Authors:  Özkan Subaşı; Mehmet Aziret; Kerem Karaman; Metin Ercan
Journal:  Int J Surg Case Rep       Date:  2019-10-23

4.  Metastatic renal cell carcinoma to pancreas and gastrointestinal tract: a clinicopathological study of 3 cases and review of literature.

Authors:  Jamshid Abdul-Ghafar; Nasir Ud Din; Ramin Saadaat; Zubair Ahmad
Journal:  BMC Urol       Date:  2021-05-25       Impact factor: 2.264

5.  Machine learning-based prediction model for late recurrence after surgery in patients with renal cell carcinoma.

Authors:  Hyung Min Kim; Seok-Soo Byun; Jung Kwon Kim; Chang Wook Jeong; Cheol Kwak; Eu Chang Hwang; Seok Ho Kang; Jinsoo Chung; Yong-June Kim; Yun-Sok Ha; Sung-Hoo Hong
Journal:  BMC Med Inform Decis Mak       Date:  2022-09-13       Impact factor: 3.298

6.  Solitary colon metastasis from renal cell carcinoma nine years after nephrectomy: A case report.

Authors:  Elaine Vo; Carlos H Palacio; Ronald Omino; Richard E Link; Yvonne Sada; Artinyan Avo
Journal:  Int J Surg Case Rep       Date:  2016-08-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.